Daiichi Kigenso Kagaku Kogyo (4082) Q4 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 2025 earnings summary
13 Jul, 2026Executive summary
Net sales decreased 4.5% year-over-year to ¥33,641 million, mainly due to production adjustments in the automobile industry and increased competition from Chinese manufacturers.
Operating profit declined 5.8% year-over-year to ¥2,282 million, impacted by one-off cost increases from the Vietnam plant launch.
Profit attributable to owners of parent fell 55.1% year-over-year to ¥632 million, partially offset by government subsidies.
Ordinary profit dropped 78.5% year-over-year, primarily due to foreign exchange losses on foreign currency-denominated assets.
Comprehensive income rose to ¥2,938 million, a 235.7% increase year-over-year.
Financial highlights
Gross profit was ¥8,352 million (24.8% of sales), up 0.5% year-over-year.
Operating profit before depreciation rose 5.9% year-over-year to ¥5,855 million.
Cash flows from operating activities decreased by ¥1,811 million year-over-year, while free cash flow increased by ¥1,084 million to ¥2,947 million.
Cash and cash equivalents at period end were ¥8,920 million, up from ¥8,289 million.
Basic earnings per share declined to ¥32.64 from ¥46.87 the previous year.
Outlook and guidance
FY2026 net sales are forecast to rise 1.1% year-over-year to ¥34,000 million, driven by growth in strategic areas.
Operating profit is projected to decline 56.2% year-over-year to ¥1,000 million due to increased costs for human capital and stable operation of the Vietnam business.
Profit attributable to owners of parent is expected to decrease 81.1% year-over-year to ¥150 million.
Basic earnings per share forecasted at ¥6.19 for the next fiscal year.
Strategic areas such as semiconductors and healthcare are expected to see sales growth, while automotive catalyst sales are forecast to decline.
Latest events from Daiichi Kigenso Kagaku Kogyo
- Operating profit rose 8.2% despite lower sales and a net loss from special charges.4082
Q2 202513 Jul 2026 - Operating profit surged 73.2% on strong healthcare and semiconductor sales, despite net income decline.4082
Q1 202513 Jul 2026 - Net income rose 19% YoY despite a 6.2% revenue decline, driven by special gains.4082
Q3 202513 Jul 2026 - Profits fell sharply due to exchange losses, but the dividend is set to rise.4082
Q1 202613 Jul 2026 - Operating profit up 17.5% YoY, with higher dividends and strong automotive catalyst demand.4082
Q3 202613 Jul 2026 - Net sales grew slightly YoY, but profit fell; guidance and dividends were raised on Vietnam cost cuts.4082
Q2 202613 Jul 2026 - Operating profit surged 52.4% YoY, but next year's outlook signals a decline in earnings.4082
Q4 202613 Jul 2026